Study of Efficacy and Safety of NIR178 and PDR001 Combination in Patients With Selected Solid Tumors and Non-Hodgkin Lymphoma

Conditions:   NSCLC;   RCC;   Pancreatic Cancer;   Urothelial Cancer;   Head and Neck Cancer;   DLBCL;   Microsatellite Stable (MSS) Colon Cancer, TNBC;   Melanoma
Interventions:   Drug: NIR178 continuosly and PDR001 combination;   Drug: NIR178 in combination with 400mg PDR001 continuously or intermittent;   Drug: NIR178/PDR001 combo- schedule to be determined
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified June 2017

http://ift.tt/2uK7XNC